| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24003 |
| Drug |
Tirzepatide |
| Brand |
Mounjaro® |
| Indication |
Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
| Rapid review commissioned |
24/01/2024 |
| Rapid review completed |
06/02/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tirzepatide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/03/2024 |
| Pre-submission consultation with Applicant |
30/04/2024 |
| Full submission received from Applicant |
10/04/2025 |
